妇科恶性肿瘤腹腔热灌注化疗临床应用专家共识(2019)

2019-02-20 中国抗癌协会妇科肿瘤专业委员会 中国实用妇科与产科杂志.2019,35(2):194-201.

2017 年中国妇科肿瘤专家遵循循证医学原则,对应用HIPEC治疗妇科肿瘤的证据进行了总结,并以此为依据制定了我国首部《妇科肿瘤腹腔热灌注治疗临床应用专家共识》。在共识的指导下,HIPEC技术在国内得到了稳步推广。2017年后,国内外多项针对HIPEC治疗妇科肿瘤的临床研究相继公布了结果,不少区域组织针对HIPEC制定了综合管理规范。这些进展和管理规范为进一步推动HIPEC技术的合理运用提供了临床

中文标题:

妇科恶性肿瘤腹腔热灌注化疗临床应用专家共识(2019)

发布日期:

2019-02-20

简要介绍:

2017 年中国妇科肿瘤专家遵循循证医学原则,对应用HIPEC治疗妇科肿瘤的证据进行了总结,并以此为依据制定了我国首部《妇科肿瘤腹腔热灌注治疗临床应用专家共识》。在共识的指导下,HIPEC技术在国内得到了稳步推广。2017年后,国内外多项针对HIPEC治疗妇科肿瘤的临床研究相继公布了结果,不少区域组织针对HIPEC制定了综合管理规范。这些进展和管理规范为进一步推动HIPEC技术的合理运用提供了临床应用证据,为解决HIPEC临床应用中的一系列问题提供了指导。根据HIPEC技术的最新进展和已获得的临床经验,我们对共识进行了更新,旨在总结HIPEC在妇科肿瘤治疗中的意义、患者获益以及HIPEC技术应用中存在的问题,为进一步总结国内经验、推动开展多中心研究、使更多中国妇科肿瘤患者从HIPEC治疗中获益奠定基础。 

拓展指南:热灌注相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=妇科恶性肿瘤腹腔热灌注化疗临床应用专家共识(2019))] GetToolGuiderByIdResponse(projectId=1, id=bfd121c001e11117, title=妇科恶性肿瘤腹腔热灌注化疗临床应用专家共识(2019), enTitle=, guiderFrom=中国实用妇科与产科杂志.2019,35(2):194-201., authorId=null, author=, summary=2017 年中国妇科肿瘤专家遵循循证医学原则,对应用HIPEC治疗妇科肿瘤的证据进行了总结,并以此为依据制定了我国首部《妇科肿瘤腹腔热灌注治疗临床应用专家共识》。在共识的指导下,HIPEC技术在国内得到了稳步推广。2017年后,国内外多项针对HIPEC治疗妇科肿瘤的临床研究相继公布了结果,不少区域组织针对HIPEC制定了综合管理规范。这些进展和管理规范为进一步推动HIPEC技术的合理运用提供了临床, cover=, journalId=null, articlesId=null, associationId=1526, associationName=中国抗癌协会妇科肿瘤专业委员会, associationIntro=, copyright=0, guiderPublishedTime=Wed Feb 20 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>2017 年中国妇科肿瘤专家遵循循证医学原则,对应用HIPEC治疗妇科肿瘤的证据进行了总结,并以此为依据制定了我国首部《妇科肿瘤腹腔热灌注治疗临床应用专家共识》。在共识的指导下,HIPEC技术在国内得到了稳步推广。2017年后,国内外多项针对HIPEC治疗妇科肿瘤的临床研究相继公布了结果,不少区域组织针对HIPEC制定了综合管理规范。这些进展和管理规范为进一步推动HIPEC技术的合理运用提供了临床应用证据,为解决HIPEC临床应用中的一系列问题提供了指导。根据HIPEC技术的最新进展和已获得的临床经验,我们对共识进行了更新,旨在总结HIPEC在妇科肿瘤治疗中的意义、患者获益以及HIPEC技术应用中存在的问题,为进一步总结国内经验、推动开展多中心研究、使更多中国妇科肿瘤患者从HIPEC治疗中获益奠定基础。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>热灌注</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=668661c001a99215" title="妇科恶性肿瘤腹腔热灌注化疗临床应用专家共识" target=_blank>妇科恶性肿瘤腹腔热灌注化疗临床应用专家共识</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=654571c001a04157" title="腹腔热灌注化疗技术临床应用专家共识(2016版)解读--胃癌腹膜转移的防治" target=_blank>腹腔热灌注化疗技术临床应用专家共识(2016版)解读--胃癌腹膜转移的防治</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=46ad21c00115397f" title="2015 细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专家共识" target=_blank>2015 细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专家共识</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E7%83%AD%E7%81%8C%E6%B3%A8" target=_blank>有关热灌注更多指南</a></ul>, tagList=[TagDto(tagId=59595, tagName=妇科恶性肿瘤), TagDto(tagId=59596, tagName=腹腔热灌注化疗)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=36, categoryName=妇产科, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9218, appHits=401, showAppHits=15, pcHits=6478, showPcHits=3579, likes=162, shares=23, comments=5, approvalStatus=1, publishedTime=Mon Mar 11 00:19:04 CST 2019, publishedTimeString=2019-02-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Mar 11 00:19:04 CST 2019, updatedBy=null, updatedName=null, updatedTime=Wed Jan 03 20:39:54 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=妇科恶性肿瘤腹腔热灌注化疗临床应用专家共识(2019))])
妇科恶性肿瘤腹腔热灌注化疗临床应用专家共识(2019)
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=965603, encodeId=9837965603a7, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/1864ac571d514b84b6d58555b164f579-HiBFG5bSXPcc.jpg, createdBy=a2805151424, createdName=14698df2m25暂无昵称, createdTime=Fri May 14 16:43:34 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954666, encodeId=ae30954666cf, content=资料好好,但无法分享,遗憾!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:28:22 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901871, encodeId=7d6e9018e12d, content=谢谢,学习了,很有用。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59f05245836, createdName=147cea3dm52暂无昵称, createdTime=Tue Nov 24 18:52:22 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362442, encodeId=6ebe362442da, content=谢谢分享学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Mar 11 09:12:01 CST 2019, time=2019-03-11, status=1, ipAttribution=)]
    2021-05-14 14698df2m25暂无昵称

    学习了,谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=965603, encodeId=9837965603a7, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/1864ac571d514b84b6d58555b164f579-HiBFG5bSXPcc.jpg, createdBy=a2805151424, createdName=14698df2m25暂无昵称, createdTime=Fri May 14 16:43:34 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954666, encodeId=ae30954666cf, content=资料好好,但无法分享,遗憾!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:28:22 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901871, encodeId=7d6e9018e12d, content=谢谢,学习了,很有用。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59f05245836, createdName=147cea3dm52暂无昵称, createdTime=Tue Nov 24 18:52:22 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362442, encodeId=6ebe362442da, content=谢谢分享学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Mar 11 09:12:01 CST 2019, time=2019-03-11, status=1, ipAttribution=)]
    2021-04-07 ms6000001015893838

    资料好好,但无法分享,遗憾!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=965603, encodeId=9837965603a7, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/1864ac571d514b84b6d58555b164f579-HiBFG5bSXPcc.jpg, createdBy=a2805151424, createdName=14698df2m25暂无昵称, createdTime=Fri May 14 16:43:34 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954666, encodeId=ae30954666cf, content=资料好好,但无法分享,遗憾!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:28:22 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901871, encodeId=7d6e9018e12d, content=谢谢,学习了,很有用。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59f05245836, createdName=147cea3dm52暂无昵称, createdTime=Tue Nov 24 18:52:22 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362442, encodeId=6ebe362442da, content=谢谢分享学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Mar 11 09:12:01 CST 2019, time=2019-03-11, status=1, ipAttribution=)]
    2020-11-24 147cea3dm52暂无昵称

    谢谢,学习了,很有用。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=965603, encodeId=9837965603a7, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/1864ac571d514b84b6d58555b164f579-HiBFG5bSXPcc.jpg, createdBy=a2805151424, createdName=14698df2m25暂无昵称, createdTime=Fri May 14 16:43:34 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954666, encodeId=ae30954666cf, content=资料好好,但无法分享,遗憾!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:28:22 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901871, encodeId=7d6e9018e12d, content=谢谢,学习了,很有用。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59f05245836, createdName=147cea3dm52暂无昵称, createdTime=Tue Nov 24 18:52:22 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362442, encodeId=6ebe362442da, content=谢谢分享学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Mar 11 09:12:01 CST 2019, time=2019-03-11, status=1, ipAttribution=)]
    2019-03-11 明月清辉

    谢谢分享学习了

    0